Rx License-Rx

23-10221-TpNCS

Interoceptomimetics: Dietary Supplements to Enhance Exercise Motivation and Performance

Enhancing exercise performance by modulating the activity of motivation-generating brain regions via stimulation of cannabinoid (CB1) receptors of the enteric nervous system. Problem: An increase in sedentary lifestyles driven by the modernization of society has led to a surge in several metabolic and neurological diseases worldwide. Although exercise is an essential and accessible method to reduce the risk of such illnesses, there is a general lack of motivation for exercising. Moreover, influencing motivation by pharmacologically engaging the brain directly has been impeded by the presence of the blood-brain barrier. Solution: Interoceptomimetics are dietary supplements that stimulate the activity of interoceptive circuits in the gut, which are neural circuits connecting the gut-innervating sensory system to the brain. These supplements alter activity in specific brain regions by stimulating the peripheral enteric neural network,...

Intelligence Memo

Owner: University of Pennsylvania

Core category: Therapeutics

Therapeutic area: Neurology

Indication: Diabetes

Modality: Small Molecule

Focus tags: Neurology, Cardiometabolic, Infectious Disease

Technology tags: Small Molecule, Cell/Gene Therapy, Biomanufacturing

Mechanism:

Development stage: Preclinical

Patent status: Patent Pending

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Neurology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with University of Pennsylvania. The practical first use case is Diabetes. Public description: Enhancing exercise performance by modulating the activity of motivation-generating brain regions via stimulation of cannabinoid (CB1) receptors of the enteric nervous system. Problem: An increase in sedentary lifestyles driven by the.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

High upside if the mechanism is measurable: Neurology is hard, but biomarkers, retinal surrogates, genetics, or target-engagement readouts can turn a vague CNS story into a fundable experiment.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

CNS translation is unforgiving: Brain exposure, target engagement, endpoint sensitivity, and placebo/noise risk can make development expensive without a biomarker-first plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Eli Lilly — Neurodegeneration leadership and biomarker-driven trial infrastructure. Biogen — CNS portfolio gap-filling and translational neurology focus. Roche — CNS diagnostics, biomarkers, and global development scale.

Development Strategy to Increase PoS

First indication: Diabetes

Study design: Mechanism-first biomarker study before any broad symptomatic endpoint trial.

Key experiments Validate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Best next experiment: Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.